362 results about "Mouse Heart" patented technology

The application provides an application of a FAP-targeted CAR-T cell in preparation of a drug for treating cardiac fibrosis in a chronic phase of myocarditis. It is found in the application that FAP-specific CAR-T cells can effectively target cells expressing mouse FAP proteins, and the CAR-T cells can effectively eliminate cells expressing mouse FAP proteins after being activated, the chimeric antigen receptor T cells effectively reduce cardiac fibrosis in a chronic phase of myocarditis in mice, and restore the function after inflammatory injury. The application develops a CAR-T therapy for myocardial fibrosis caused by a chronic phase of myocarditis, and the chimeric antigen receptor T cells expressing a targeted fibroblast activation protein can recognize activated myocardial fibroblasts, and significantly reduce cardiac fibrosis after inflammatory injury and restore the function.

Provided is a method for screening myocardial therapeutic targets for ischemic heart failure by using single-cell sequencing, which method comprises the following steps: S1, sample preparation; S2, construction of a single-cell expression matrix; S3, cell quality control; S4, cell type annotation; S5, cell communication analysis; and S6, co-expression network analysis. The provided method for screening myocardial therapeutic targets for ischemic heart failure by using single-cell sequencing comprises performing single-cell sequencing on hearts of healthy mice and IHF mice, screening for cell types with significant differences in cardiac transcriptional profiles of the healthy mice and IHF mice, then exploring interaction characteristics of various types of cells in malignant fibrotic IHF hearts, revealing potential regulatory modules and pathways related to malignant myocardial fibrosis in single-cell expression data of IHF hearts, and performing screening to obtain Pdgfb and Tnfsf12 genes which can be used as therapeutic targets for treating myocardial fibrosis in ischemic heart failure.

The invention discloses an extraction method of safflower leaf exosome-like nano-vesicles and application of the safflower leaf exosome-like nano-vesicles in preparation of drugs for preventing and treating adriamycin-induced cardiotoxicity, fresh safflower leaves are taken and cleaned, a PBS solution is added for crushing and filtering, filtrate is collected and continuously centrifuged, supernate is taken and subjected to ultracentrifugation, precipitates are collected after centrifugation, and the safflower leaf exosome-like nano-vesicles are obtained; and filtering and sterilizing by using a filter membrane to obtain the safflower leaf exosome-like nano-vesicles. The carthamus tinctorius leaf exosome-like nano-vesicles can significantly improve the heart function of doxorubicin-induced cardiotoxic mice; myocardial injury induced by doxorubicin can be repaired, and myocardial fibrosis induced by doxorubicin can be inhibited; the content of a myocardial injury marker lactic dehydrogenase in body serum can be reduced, a new treatment strategy is provided for preventing and treating adriamycin-induced cardiotoxic diseases, and the application prospect is good.

The invention discloses application of a JMJD6-targeted reagent in preparation of a medicine for promoting myocardial cell proliferation. The medicine can promote myocardial cell proliferation after myocardial infarction and reduce the myocardial fibrosis scar area caused by myocardial infarction. AAV9 myocardial specific overexpression virus and JMJD6 myocardial specific knockout mice are utilized, and the positive effect of JMJD6 in promotion of P1 cardiac apex resection of newborn mice and regeneration and repair of injured hearts after myocardial infarction of adult mice is disclosed for the first time; the specific mechanism is that JMJD6 depends on the activity of histone demethylase, enrichment of active modification H4R3me2a and H3R2me2s in a PDK4 promoter region is removed, transcriptional expression of the H4R3me2a and the H3R2me2s is inhibited, an impaired heart energy substrate utilization mode is stimulated to be increased and converted from fatty acid oxidation energy supply to glycolysis oxidation energy supply, and then adult myocardial cell proliferation is effectively promoted. The regeneration and repair capability of the heart after myocardial infarction is greatly improved, and a new effective target spot is provided for clinical treatment of myocardial injury.

The invention discloses a recombinant adeno-associated virus vector for targeted delivery of VEGF-C (vascular endothelial growth factor-C) and application of the recombinant adeno-associated virus vector in promoting endocardial differentiation to treat coronary heart disease. The rAAV vector comprises transgene for coding VEGF-C protein or VEGF-C protein functional variant and a tissue-specific promoter operably connected to the transgene, wherein the tissue specific promoter is capable of driving the transgene to be specifically expressed in the heart endothelial cells. According to the treatment method developed by the invention, specific expression of the Vegfc gene in the heart is driven by using an ICAM2 promoter with targeting to endothelial cells, and a remarkable curative effect is shown in a myocardial infarction model mouse. The therapeutic scheme provides a new effective strategy for intervention and treatment of myocardial infarction and chronic heart failure, and has the advantages of high safety, long gene expression duration, extremely low immune response to a host and the like.

The invention provides an application of a CGRP inhibitor in preparation of a medicine for treating myocardial infarction or heart failure, relates to the technical field of biomedicine, and has the technical key points that the invention provides the CGRP inhibitor Rimegepant and provides an effect of the CGRP inhibitor Rimegepant in myocardial infarction and heart failure, and the CGRP inhibitor Rimegepant can be used for preparing a medicine for treating myocardial infarction or heart failure. The myocardial infarction and / or heart failure model is constructed through left anterior descending branch coronary artery ligation. In-vitro experiments verify that the expression of the CGRP receptor protein in the heart of a mouse after heart failure is increased, and prove that the CGRP inhibitor Rimegeant can effectively inhibit the expression of the CGRP receptor protein, and further research is carried out, so that a potential treatment strategy is provided for drug research and development. The in-heart CGRP receptor inhibitor can obviously relieve the myocardial infarction and / or heart failure course of mice, and down-regulate the protein expression of the CGRP receptor at the same time.

The invention discloses a construction method and application of an animal model for evaluating cardiotoxicity of antitumor drugs, sodium carboxymethyl cellulose (CMC-Na) with extremely low cost is adopted to replace matrigel, a tumor-bearing mouse model with high stability can be constructed at low cost, and experimental verification shows that 4T1 cells are resuspended by using a 0.7% CMC-Na solution, and the tumor formation rate of subcutaneous inoculation reaches gt; 95%. The tumor microenvironment-mediated cardiac injury critical period is accurately captured, and the constructed tumor-bearing mouse model is the optimal tumor-bearing mouse model for evaluating the cardiotoxicity of an antitumor drug (adriamycin) in the tumor microenvironment in the third week after the mouse has a 50mm < 3 > tumor.

Example cardiac pump systems are disclosed. An example cardiac pump system includes a cardiac pump coupled to a console. Further, the console includes a first display including a first visual representation of a first parameter of the cardiac pump system. Further, the first display includes a first status indicator and a second status indicator corresponding to the first parameter. Further, the first display is configured to display the first status indicator when the first parameter satisfies a first condition, and wherein the first display is configured to display the second status indicator when the first parameter satisfies a second condition.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke. By constructing a mouse model of heatstroke-induced myocardial injury and observing indicators such as rectal temperature, blood routine tests, blood biochemistry, oxidative stress, and cardiac function, this invention found that lemon balm glycosides can significantly reduce the increase in rectal temperature caused by heatstroke in mice, increase the content of red blood cells and albumin in plasma, and reduce the level of oxidative stress in myocardial cells. Therefore, the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke is proposed.

The invention relates to the technical field of mode recognition, in particular to a cardiac image data processing system based on deep learning, which comprises an initial map construction module, an artifact branch pruning module, a fracture path repairing module and a topological smooth output module. According to the method, initial topology containing node coordinates is constructed, the maximum inscribed circle area is calculated to generate circulation attributes, virtual blood flow injection simulation and flow resistance calculation are utilized to accurately quantify branch traffic capacity, artifact interference is eliminated according to the matching relation between the blood flow proportion and the flow resistance, and suspended node geometric features and a path texture sequence are combined, so that the branch traffic capacity is accurately quantified. A graph neural network is utilized to predict a connection probability to repair a fracture path, a node coordinate weighted updating mechanism is matched to guarantee smoothness and continuity of a topological structure, the problems of artifact confusion and path fracture in a traditional method are effectively solved, and the construction accuracy and automation level of a heart structure model are remarkably improved.

The application provides a kind of replacement valve device and its support by catheterization, it is related to heart valve technical field.The replacement valve support by catheterization includes support main body, anchoring structure, skirt support structure and sealing membrane.The sealing membrane is circumferentially closed cylindrical structure, sealing membrane includes the first sealing section and the second sealing section being arranged along the axial direction and being connected with each other, the first sealing section is tightly arranged on part or all of skirt support structure, the second sealing section is tightly arranged on part or all of support main body;Sealing membrane is arranged on the inner side and / or outer side of skirt support structure and support main body.The application can solve the problem that sealing membrane and valve support do not fit in the prior art, poor sealing, leading to sealing membrane in blood, leading to paravalvular leakage or causing other complications, with high degree of fit, good sealing, can avoid sealing membrane in blood, effectively avoid paravalvular leakage or cause other complications.

The present application provides a method for improving the yield and purity of cardiomyocytes derived from pluripotent stem cells, which comprises one or more of the following steps: EB formation culture; cardiac progenitor cell induction and differentiation culture; cardiomyocyte induction and differentiation culture; cardiomyocyte maturation culture; and cardiomyocyte purification culture. In another aspect, the present application also provides a culture medium, a medium combination, a cell culture system, and a kit for improving the yield and purity of cardiomyocytes derived from pluripotent stem cells.

Disclosed is a system for monitoring a heart condition in a companion animal. The system can collect electrocardiogram data of a companion animal through a capacitive electrocardiogram sensor without prior preparation such as hair removal, collect phonocardiogram data and ballistocardiogram data through a phonocardiogram sensor and a ballistocardiogram sensor, and generate cardiogram-integrated data available for diagnosing a heart condition in the companion animal by merging the electrocardiogram data, the phonocardiogram data, and the ballistocardiogram data.

A heart pump assembly includes an elongate catheter with a proximal portion and a distal portion, a rotor at the distal portion of the elongate catheter, a driveshaft, and a bearing. The rotor can include an impeller blade shaped to induce fluid flow in a first axial direction. The drive shaft may be coupled to or integrally formed with a proximal end of the rotor and can include a pump element formed in a surface of the drive shaft. The bearing can include a bore into which the drive shaft extends. The pump element is shaped so as to induce fluid flow through the bore in a second axial direction which can be the same or opposite to the first axial direction.

The application belongs to the technical field of biological medicine, and discloses application of targeted inhibition of TRIM47 in preparation of a drug for preventing or treating myocardial ischemia-reperfusion injury. By establishing a mouse myocardial ischemia-reperfusion injury model, it is found that, compared with a model group, specific knockout of the TRIM47 gene in the heart can significantly improve the heart function of a myocardial ischemia-reperfusion injury mouse, reduce the infarct area after myocardial reperfusion, and also reduce the hypertrophy of myocardial cells and matrix deposition of the mouse, and improve myocardial remodeling. Based on the above findings, TRIM47 can be used as an action target of a myocardial ischemia-reperfusion injury treatment drug, and an inhibitor thereof can be used for preparing a drug for preventing or treating myocardial ischemia-reperfusion injury.

The invention discloses a valve preparation method. The method comprises the following steps: performing decellularization treatment on a bovine pericardium material to be treated; enhancing the porosity of the decellularized bovine pericardium material through a physical and / or chemical method so as to promote the regeneration of native valve leaflet cells and tissues, and obtaining a composite material; and cutting the leaflet of the composite material to obtain the valve. The bovine pericardial valve which is high in durability, free of anticoagulation, excellent in biocompatibility, excellent in calcification resistance and low in immunogenicity can be prepared, and therefore the purpose of treating heart valve diseases is achieved.

The invention belongs to the technical field of electrochemical monitoring, and particularly relates to a physiological and biochemical diagnosis and treatment integrated implantable heart flexible sensor which comprises an insulating substrate, a counter electrode, a working electrode, a reference electrode and two electrocardiogram electrodes, graphene aerogel loaded with a monitoring substance is adhered to the working end of the working electrode, and the monitoring substance is a substance for monitoring biochemical signals. The implantable heart flexible sensor provided by the invention can realize trinity collaborative operation of physiological signal monitoring, biochemical signal monitoring and treatment functions. In the aspect of monitoring physiological signals, the system has the advantages of high signal-to-noise ratio, dynamic adaptability, long-term stability and the like; in the aspect of monitoring biochemical signals, the sensor has the advantages of high sensitivity and high stability; in the aspect of treatment, the device has the characteristics of promoting electrical signal conduction, being flexibly attached to the heart, providing three-dimensional structure support regeneration and being stable for a long time.

The utility model belongs to medical image examination auxiliary equipment technical field, concretely relates to a support device based on heart magnetic resonance examination. The device includes first support board, has the sliding block on first support board, is fixedly connected with the sliding block on the second support board, has the lifting frame on the second support board and goes up and down, the clamping plate is connected in the linear sliding of lifting frame, still rotationally connects the adjusting screw on the lifting frame, and the adjusting screw is connected with clamping plate screw thread. Through above -mentioned structure, the vertical height and horizontal position adjustment of clamping plate can be realized, are favorable to the body position fixation to the child patient, and further guarantee the stability of the position of the sick child in the examination process, improve the acquisition quality of heart magnetic resonance image.

The invention discloses a method for measuring the pressure in the heart cavity of a mouse, and relates to the technical field of experimental animal medical detection, and the method comprises the following steps: cutting an incision of about 1cm in the neck of the mouse; placing two sutures below the common carotid artery, and ligating the common carotid artery by using the suture at the distal end; the other section of suture line is placed in the middle of the right common carotid artery, the carotid artery is lifted up, the blood filling condition is observed, an opening is formed in the blood vessel, a pressure volume catheter is inserted, and meanwhile the suture line at the telecentric end is slightly pulled backwards to prevent bleeding; the pressure volume catheter is inserted into the left ventricle through the right common carotid artery, and the left ventricle pressure maximum rising rate and the left ventricle pressure maximum falling rate are collected. By means of the carotid artery approach, serious trauma caused by thoracotomy can be prevented, and the cardiac physiology can be possibly affected by the operation. Therefore, the carotid artery approach is more suitable for a long-time pressure collection experiment.

A magnetic heart valve for a cardiovascular simulator based on magnetic field operation and a manufacturing method thereof, and a soft magnetically regulated heart valve apparatus using the same is disclosed. This magnetic heart valve includes magnetic particles, and an elastic silicone composite material, it has a circular plate shape, at least one heart valve shape is formed within the circular plate shape, and at least one heart valve shape is apart from each other to allow the circular plate shape to freely bend upward or downward.

The invention discloses a construction method of a coronary artery microcirculation disturbance cell model, and belongs to the technical field of biological medicine. According to the method, mouse heart microvascular endothelial cells (MCMEC) are taken as objects, tetrachlorohydroquinone (TCHQ) is used for treating for 6 hours at the concentration of 20-40 [mu] M, and CMD typical characteristics such as apoptosis, increase of reactive oxygen species (ROS), reduction of nitric oxide (NO) and release of inflammatory factors (TNF-alpha and IL-1beta) of the cells are induced. The TCHQ is applied to construction of the CMD model for the first time, and the model is stable, good in repeatability and capable of being used for CMD pathogenesis research and drug screening.

The invention relates to a method for producing an animal model of heart failure. The method comprises the step of weakening or deleting DDB1 protein function in myocardial cells of the animal model. The present application demonstrates that nuclear DDB1 co-agglomerates with MEF2C to control NAD + biosynthesis as well as ion homeostasis genes in the heart, and the lack of which results in the development of HFpEF. Development of HFpEF in a'double strike 'mouse model can be reversed through AAV-mediated DDB1 overexpression in myocardial cell nucleuses. Therefore, it is detected that DDB1 coordinates NAD + biosynthesis and ion homeostasis to protect the heart from being affected by ejection fraction retention heart failure caused by obesity, and the scheme of the application has therapeutic significance on treatment of obesity / diabetes HFpEF.

Methods and apparatus are provided for determining a disengagement status of a patient associated with a mechanical circulation support device. The method includes: receiving a set of signals from the mechanical circulation support device implanted in a heart of a patient; determining, using a computer processor, a set of features based at least in part on the set of signals; providing the set of features as input to a machine learning model trained to output a disengagement state of the patient; and displaying, on a user interface associated with the mechanical cycle support device, an indication of the disengaged state of the patient output from the machine learning model.

The application discloses application of pentagalloyl glucose (PGG) in preparation of an anti-doxorubicin cardiotoxicity medicine. The process is as follows: a myocardial cell H9C2 injury model is induced and established by doxorubicin (DOX), and a minimum concentration of the myocardial cell injury induced by DOX is determined. After 20 muM of PGG is added to a treatment group, DOX-induced H9C2 cell apoptosis can be significantly improved. A mouse myocardial injury model is induced and established by DOX, compared with a doxorubicin group, the left ventricular systolic fraction (FS%) and the ejection fraction (EF%) of mice in the doxorubicin+pentagalloyl glucose group are significantly increased, the myocardial fiber structure is improved, cytoplasm vacuolization is reduced, the serum cTnT and BNP levels are reduced, and the ROS level is reduced. It is proved by the above experiments that the pentagalloyl glucose can significantly reduce DOX-induced myocardial toxicity.

The invention provides an ultrasonic imaging method and device for an animal heart, equipment and a storage medium. The ultrasonic imaging method of the animal heart comprises the following steps: acquiring a real-time ultrasonic section image of the animal heart; identifying a key point and a probe emission point in the ultrasonic section image; acquiring an M line of the real-time ultrasonic section image based on the key point and the probe transmitting point; acquiring a real-time ultrasonic section image of an M mode based on the M line; and automatically acquiring measurement information based on the real-time ultrasonic section image of the M mode. The M-mode ultrasonic section image is automatically obtained through an artificial intelligence method, and the corresponding measurement item is automatically measured based on the M-mode ultrasonic section image, so that the efficiency of ultrasonic heart examination is greatly improved.

The application discloses application of a lipoic acid analogue in preparation of a product for relieving myocardial cell hypertrophy, and the lipoic acid analogue DMAE-LA is N -(2-(dimethylamino)ethyl)-5-(1,2-dithiopentyl-3-yl)valeric amide. DMAE-LA can effectively reduce ISO-induced myocardial hypertrophy of mice, reduce heart weight index and ANP and BNP expression, and significantly improve heart function. A small dose (2-10 μM) of a lysosome-targeting lipoic acid analogue DMAE-LA can effectively improve Ang II-induced myocardial hypertrophy and oxidative stress in H9c2 cells, and the protective effect is better than that of a high dose (200-400 μM) of LA. As a new substitute of traditional LA, DMAE-LA shows great potential for prevention and treatment of cardiovascular diseases.

1. Name of the product in this design: Graphical User Interface for Monitoring Multiple Medical Parameters in Electronic Equipment. 2. Purpose of this design: An electronic device. 3. The key design features of this product are the graphical user interface content on the screen. 4. The image or photograph that best illustrates the design's key features: the front view. 5. For conventional designs, the left view of electronic devices is omitted; for conventional designs, the right view of electronic devices is omitted; for conventional designs, the top view of electronic devices is omitted; for conventional designs, the bottom view of electronic devices is omitted; for conventional designs, the rear view of electronic devices is omitted. 6. Application of the graphical user interface: This graphical user interface can be displayed on electronic devices such as mobile phones, computers, tablets or medical instruments to visualize multiple physiological parameters of the patient. These physiological parameters are divided into specific parameters and routine parameters. The variation range, real-time value and real-time fluctuation curve of each parameter are presented on the graphical user interface. It is suitable for multiple medical scenarios such as high-risk critical care, ICU / brain, cardiology, routine care and obstetrics. 7. Human-computer interaction method of graphical user interface: This graphical user interface is the interface for the "high-risk critical care" scenario. When clicking "ICU / brain", "heart", "routine" or "obstetrics", it will switch to the interface of the corresponding medical scenario.

The invention discloses application of Psammatlysene D and a derivative thereof in preparation of a medicine for resisting chronic liver diseases, and belongs to the technical field of medicines. The technical scheme of the invention comprises the application of the Psammaglyene D in preparation of a product for resisting chronic liver diseases. The Psammatlyene D can inhibit the growth of LX2 cells, reduce liver function indexes ALT and AST, and relieve the degree of hepatic fibrosis in a mouse body; the growth of liver cancer cells can be inhibited in vivo and in vitro, and a synergistic effect can be generated with sorafenib; meanwhile, the anti-proliferation ability is also shown in sorafenib drug-resistant liver cancer. The derivative B12 of the Psammatlysene D has a stronger in-vitro anti-hepatic fibrosis effect, and the C11 has a very weak inhibition capability on hERG (human endothelial growth factor) and has no potential cardiotoxicity. The results show that the Psammaglyene D has relatively strong capabilities of resisting hepatic fibrosis, inhibiting liver cancer development and relieving sorafenib drug-resistant liver cancer, and the Psammaglyene D and C11 can be used as potential lead compounds for the development of anti-hepatic fibrosis and anti-liver cancer drugs, and are finally applied to the treatment of chronic liver diseases.

The invention discloses a method for constructing a chronic heart failure co-disease depression animal model through composite intervention, and belongs to the technical field of disease animal model construction. Firstly, a left anterior descending coronary branch ligation operation is performed on a mouse to construct a heart failure model, and then a depression model is constructed by constraining mouse superposition. After composite modeling, the systolic function of the mouse is obviously reduced, the activity ability is weakened, and myocardial fibrosis and hippocampal tissue damage occur, which indicates that the heart failure co-disease depression model is successfully modeled. The animal model construction method has a good application prospect in research on the pathogenesis, biomarkers and treatment means of heart failure co-disease depression.